Heron Therapeutics (HRTX) Receivables (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Receivables came in at $83.7 million in Q1 2026, up 6.3% YoY from $78.7 million in Q1 2025, and down 6.75% on a QoQ basis from $89.7 million in Q4 2025.
Heron Therapeutics (HRTX) Receivables (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 12 years of Receivables data on file, last reported at $83.7 million in Q1 2026.
- Quarterly Receivables rose 6.3% year-over-year to $83.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.7 million (up 6.3% YoY) and the FY2025 annual result came in at $89.7 million, up 13.4% from the prior year.
- Receivables fell to $83.7 million in Q1 2026, from $89.7 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $89.7 million in Q4 2025 to a low of $40.3 million in Q2 2022.
- A 5-year average of $66.3 million and a median of $67.0 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables decreased 5.43% — and 2023, when it jumped 90.29%.
- Tracing HRTX's Receivables over 5 years: stood at $52.2 million in 2022, then gained by 15.24% to $60.2 million in 2023, then jumped by 31.56% to $79.1 million in 2024, then rose by 13.4% to $89.7 million in 2025, then slipped by 6.75% to $83.7 million in 2026.
- The last three Receivables figures came in at $83.7 million (Q1 2026), $89.7 million (Q4 2025), and $81.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 89.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.57 Mn |
| Mar 31, 2026 | 83.69 Mn |
| Dec 31, 2025 | 89.75 Mn |
| Sep 30, 2025 | 81.05 Mn |
| Jun 30, 2025 | 79.93 Mn |
| Mar 31, 2025 | 78.74 Mn |
| Dec 31, 2024 | 79.14 Mn |
| Sep 30, 2024 | 67.04 Mn |
| Jun 30, 2024 | 73.71 Mn |
| Mar 31, 2024 | 65.32 Mn |
| Dec 31, 2023 | 60.16 Mn |
| Sep 30, 2023 | 63.80 Mn |
| Jun 30, 2023 | 76.69 Mn |
| Mar 31, 2023 | 51.45 Mn |
| Dec 31, 2022 | 52.20 Mn |
| Sep 30, 2022 | 42.19 Mn |
| Jun 30, 2022 | 40.30 Mn |
| Mar 31, 2022 | 41.10 Mn |
| Dec 31, 2021 | 35.60 Mn |
| Sep 30, 2021 | 43.09 Mn |